동시 뇌전도 및 기능 MRI 중 뇌전도 데이터의 신뢰할 수 있는 획득

Executive Industry Relevance

Reliable EEG data acquisition during simultaneous EEG-fMRI is critical for de-risking target validation in neuroscience drug discovery, where subtle electrophysiological changes inform mechanistic understanding of disease pathways. This protocol enhances predictive confidence by ensuring data quality and reproducibility, directly supporting early discovery decisions in target identification and pathway clarification. Its adaptability across research and clinical settings enables enterprise reuse, reducing variability in cross-functional collaborations and improving translational continuity from discovery to preclinical validation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through high-fidelity EEG signal acquisition during simultaneous fMRI, clarifying neuronal activity patterns linked to disease mechanisms.
• Operational Value: Standardizes electrode placement and impedance monitoring, reducing technical variability and improving data reliability across studies.
• Predictive Value: Supports detection of subtle EEG changes in epilepsy and neurocognitive models, aiding in biomarker alignment and mechanistic de-risking of targets.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems (human subjects) for downstream workflows by ensuring EEG data quality, enabling reliable compound evaluation in neurocognitive and epileptic models.
• Operational Value: Utilizes readily available medical products and standardized procedures, promoting assay standardization, scalability, and platform reuse across sites.
• Predictive Value: Facilitates identification of subtle EEG events in single-trial ERPs, improving screening readiness for compounds targeting neural network dysfunction.

Translational & Preclinical Research

• Scientific Value: Supports translational biomarker alignment by providing analyzable EEG data correlated with hemodynamic responses, bridging discovery and preclinical validation.
• Operational Value: Ensures continuity from discovery through preclinical work by minimizing artifacts (e.g., ECG, muscle) that could confound interpretation across study phases.
• Predictive Value: Enhances risk-adjusted advancement decisions by delivering clean EEG signals free from machinery vibrations and electrode bridging, increasing confidence in target engagement readouts.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from Early Discovery through Lead Identification to Preclinical work, supporting hypothesis testing, pathway clarification, and biological de-risking where EEG-fMRI provides complementary temporal and spatial resolution for target validation.

• Discovery Biology: Supports hypothesis testing by enabling accurate measurement of neuronal electrographic events during fMRI, clarifying pathway involvement in disease models.
• Screening: Delivers assay readiness through reproducible EEG data acquisition, with low impedance thresholds (<20 kΩ) ensuring signal quality for compound screening in neurocognitive and epilepsy models.
• Analytics: Provides quantitative dependent variable measurements (EEG signal amplitude, artifact-free epochs) that enable comparison of conditions and target modulation effects.
• Translational Research: Connects discovery to preclinical continuity by yielding EEG data suitable for correlation with BOLD responses, supporting biomarker validation in disease-relevant systems.
• Enterprise Reuse: Framed as a reusable capability due to its simplicity, use of standard medical products, and adaptability across EEG-fMRI applications, reducing implementation burden.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target validation, reduction of mechanistic ambiguity through clean EEG signal acquisition.
• Operational Value: Standardization, reproducibility, and scalability via protocol-driven electrode preparation and wire immobilization.
• Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk by ensuring data reliability early in discovery.
• Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on high-quality, analyzable EEG data from simultaneous EEG-fMRI studies.

Implementation Considerations

• Required scientific expertise in EEG electrode placement, impedance monitoring, and MRI safety protocols.
• Instrumentation needs include MRI-compatible EEG/bipolar amplifiers, optic fiber connectors, and non-ferromagnetic sandbags for wire immobilization.
• Cross-team standardization requires training on head circumference measurement, cap sizing, and abrasive gel application to maintain electrode-skin interface quality.
• Adaptation considerations include adjusting pillow placement and headset selection for resting state vs. task-based acquisitions while maintaining coil integrity.
• Practical limitations include the need to avoid excessive gel application to prevent electrode bridging and ensure subject comfort during prolonged supine positioning.

Biopharma FAQs